Generic 180-Day Exclusivities Might Be Imperiled By ANDA Stability Guidance
Executive Summary
Industry experts predict generic company pushback on some aspects of Q&A draft guidance and worry about unintended consequences, including impact on drug master files.
You may also be interested in...
ANDA Stability Requirements To Be Broadly Grandfathered, FDA Says
In a win-win for agency and industry, generic applications submitted before deadline for new stability requirements still will be judged by old standards, even if the ANDAs are amended or resubmitted.
ANDAs To Include Six Months Of Stability Test Data Under FDA Draft Guidance
The agency advises sponsors to follow the stability testing recommendations in the International Conference on Harmonization guidances; three companies submit comments seeking clarification from FDA.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.